<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1715">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834856</url>
  </required_header>
  <id_info>
    <org_study_id>MP0420-CP204</org_study_id>
    <secondary_id>2021-000365-33</secondary_id>
    <nct_id>NCT04834856</nct_id>
  </id_info>
  <brief_title>Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients</brief_title>
  <official_title>A Phase 2a Open Label, Non-comparative, Single Dose Escalation Study to Evaluate the Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep in Patients With Symptomatic COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Partners AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Partners AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how ensovibep is distributed throughout the body, the viral&#xD;
      clearance and the tolerability of ensovibep in patients with symptomatic COVID-19 disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>up to day 29</time_frame>
    <description>Changes from baseline to each time point of measurement in SARS-CoV-2 viral load in nasopharyngeal swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 viral cultures</measure>
    <time_frame>up to day 29</time_frame>
    <description>Changes from baseline to each time point of measurement in SARS-CoV-2 viral cultures cultivated from nasopharyngeal swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 PCR days to negativity</measure>
    <time_frame>up to day 29</time_frame>
    <description>Duration in days to SARS-CoV-2 PCR negativity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed maximum concentration (Cmax)</measure>
    <time_frame>up to day 91</time_frame>
    <description>The maximum observed concentration (Cmax) is estimated based on the serum concentrations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-Life (T½)</measure>
    <time_frame>up to day 91</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>up to day 91</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the concentration-time curve from time zero extrapolated to infinity time (AUCinf)</measure>
    <time_frame>up to day 91</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>up to day 91</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance of the drug from plasma (CL)</measure>
    <time_frame>up to day 91</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss)</measure>
    <time_frame>up to day 91</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>14 Common Covid-19 Related Symptoms score</measure>
    <time_frame>up to day 29</time_frame>
    <description>Changes in the assessment of 14 Common Covid-19 Related Symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent (serious) adverse events ((S)AEs) and AEs of Special Interest (AESIs) including Infusion-related reactions (IRRs)</measure>
    <time_frame>up to day 91</time_frame>
    <description>Treatment-emergent (S)AEs and AESIs, including infusion-related reactions (IRRs) will be assessed throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication</measure>
    <time_frame>up to day 91</time_frame>
    <description>Intake of concomitant medication will be assessed throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Heart Rate (bpm)</measure>
    <time_frame>up to day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)</measure>
    <time_frame>up to day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Respiratory Rate (breaths per minute)</measure>
    <time_frame>up to day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Body Temperature (°C)</measure>
    <time_frame>up to day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Oxygen Saturation (SpO2)</measure>
    <time_frame>up to day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests (hematology and blood chemistry)</measure>
    <time_frame>up to day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations (symptom directed)</measure>
    <time_frame>up to day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability at injection site</measure>
    <time_frame>up to 90 min post dose</time_frame>
    <description>Local tolerability at injection site will be assessed via Visual Infusion Phlebitis score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ensovibep dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ensovibep dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ensovibep</intervention_name>
    <description>The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.</description>
    <arm_group_label>ensovibep dose 1</arm_group_label>
    <arm_group_label>ensovibep dose 2</arm_group_label>
    <other_name>MP0420</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or non-pregnant women, between 18 and 70 years on the day of inclusion.&#xD;
&#xD;
          -  Presence of one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat,&#xD;
             malaise, fatigue, headache, muscle pain, gastrointestinal symptoms, or shortness of&#xD;
             breath with exertion.&#xD;
&#xD;
          -  Positive test for SARS-CoV-2 in upper respiratory swab on the day of dosing (rapid&#xD;
             antigen test).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring hospitalization at time of screening, or at time of study drug&#xD;
             administration.&#xD;
&#xD;
          -  Oxygen saturation (SpO2) ≤ 93 percent (%) on room air at sea level, respiratory rate ≥&#xD;
             30 per minute, or heart rate ≥125 per minute.&#xD;
&#xD;
          -  Any serious concomitant systemic disease, condition, or disorder that, in the opinion&#xD;
             of the investigator, should preclude participation in this study.&#xD;
&#xD;
          -  Any co-morbidity requiring hospitalization or surgery within &lt;7 days, or that is&#xD;
             considered life-threatening within 29 days.&#xD;
&#xD;
          -  A patient reported history (prior to the current episode) of a positive SARS-CoV-2&#xD;
             serology test or a history of PCR confirmed SARS-CoV-2 infection.&#xD;
&#xD;
          -  Prior or concurrent use of SARS-CoV-2 antiviral medication, including convalescent&#xD;
             serum or anti-viral antibodies.&#xD;
&#xD;
          -  Concurrent enrollment in any other type of medical research for improving COVID-19&#xD;
             outcomes or that is judged by the investigator not to be scientifically or medically&#xD;
             compatible with this study.&#xD;
&#xD;
          -  Women that are currently breast feeding, pregnant, or plan to get pregnant during the&#xD;
             duration of the trial.&#xD;
&#xD;
          -  Severe immunocompromised status (primary immunodeficiency, supraphysiological dose of&#xD;
             systemic corticosteroids, transplant patients, known untreated HIV and CD4 T-cells&#xD;
             &lt;200/microliter) or use of any immunosuppressants that, in the opinion of the&#xD;
             investigator, should preclude participation in this study.&#xD;
&#xD;
          -  Subjects at high risk for of COVID-19 related complications or mortality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director MPAG</last_name>
    <phone>+41447557700</phone>
    <email>info@molecularpartners.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principle Investigator</last_name>
      <phone>+31715246400</phone>
      <email>idvisser@chdr.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Corona</keyword>
  <keyword>DARPin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

